Stem-cell start-ups seek to crack the mass-production problem

Eric Bender

Nature, 2021, vol. 597, issue 7878, S20-S21

Abstract: Commercial outfits are building the tools and know-how to manufacture treatments using induced pluripotent stem cells in the quantities required for clinical use.

Keywords: Stem cells; Biotechnology; Therapeutics; Industry (search for similar items in EconPapers)
Date: 2021
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/d41586-021-02627-y Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:597:y:2021:i:7878:d:10.1038_d41586-021-02627-y

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/d41586-021-02627-y

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().